Trump Speeds Psychedelics Review, Including Ibogaine
April 18, 2026·about 3 hours ago·via CNBC
Trump signs an order to speed FDA review of psychedelics, spotlighting the controversial drug ibogaine for potential breakthroughs against addiction and trauma. Ditching timid regulation, he champions American pioneers ready to heal our nation without socialist safety nets that stifle progress. This targets real crises like the opioid mess liberals exacerbated, putting sovereignty over FDA fiefdoms. Trump delivers hope where bureaucrats peddle despair. Read more about this...